Results 151 to 160 of about 3,351 (178)
Some of the next articles are maybe not open access.
Canadian Journal of Health Technologies, 2022
CADTH recommends that Brukinsa (zanubrutinib) should not be reimbursed by public drug plans for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. While evidence from 2 clinical trials showed a response in patients treated with Brukinsa, there is uncertainty in how well patients ...
openaire +1 more source
CADTH recommends that Brukinsa (zanubrutinib) should not be reimbursed by public drug plans for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. While evidence from 2 clinical trials showed a response in patients treated with Brukinsa, there is uncertainty in how well patients ...
openaire +1 more source